The Criteria of Until Progression for Drug Discontinuation in EGFR Inhibitor Therapy: Right or Wrong?
Background To review the current progress in the criteria of drug discontinuation in EGFR inhibitor therapy.Methods A review of the literature encompassing the criteria of drug discontinuation in EGFR inhibitor therapy was performed.Results The clinical success of EGFR kinase inhibitors as therapeutic agents has prompted substantial interest in the further development and clinical testing for a wide variety of malignancies.However, much of study has been focused on the efficacy of tyrosine kinase inhibitors, and relatively, little study has been done on the criteria for drug discontinuation.The current standard of drug discontinuation is ”until progression” and it is based on the change of tumor size.But the tumor size has no relations with the gene expression which determined the TKI effect in the final analysis, and it is difficult to predict when the TKI discontinued reasonably.Conclusion Nevertheless clinical evaluation of the criteria for drug discontinuation is still in its early days, some promising findings have begun to emerge.It is hoped that, with the improving knowledge of EGFR and its inhibitors, the criteria for drug discontinuation in EGFR inhibitor therapy make change and get progress.
EGFR drug discontinuation acquired drug-resistance
Hong-qing Zhuang Jun Wang Ping Wang Lu-jun Zhao Zhi-yong Yuan
Department of Radiotherapy, Tianjin Medical University Cancer Institute and Hospital, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin lung cancer center, Tianjin, PR China
国内会议
北京大学医学部放射肿瘤学系成立大会暨北京大学第二届国际放射肿瘤学术论坛
北京
英文
198-212
2012-05-23(万方平台首次上网日期,不代表论文的发表时间)